HTG MOLECULAR DIAGNOSTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0025 USD | 0.00% |
|
0.00% | +92.31% |
| 2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
| 2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to HTG Molecular Diagno...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.
Calendar
2025-05-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +92.31% | 5.54K | |
| -40.31% | 2.95B | |
| +18.54% | 1.88B | |
| -2.22% | 1.63B | |
| +34.33% | 1.34B | |
| -16.73% | 959M | |
| -22.64% | 888M | |
| +7.58% | 842M | |
| -25.66% | 623M | |
| +11.08% | 513M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- Transcript : HTG Molecular Diagnostics, Inc., Q2 2021 Earnings Call, Aug 12, 2021